Replies to post #394065 on Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

"2-6% royalty on Brilacidin for Ulcerative Proctitis (AlfaSigma)
6% royalty on Brilacidin for anti-fungal (Fox Chase)"

FWIW:
IPIX booked $18,000 in Revenue in the latest 10K: "On May 3, 2022, the Company received payment of $18,000 from FCCDC based on FCCDC’s third-party license of broad-spectrum anti-fungals and a separate agreement between the Company and FCCDC."

This suggests that Fox got a smaller upfront payment from Basilea ($300,000) than IPIX got from AlfaSigma for UP ($400,000).

Fox's license to Basilea wasn't exclusively for the anti-fungals licensed to Fox by IPIX. Per a Fox Research Fellow:
"The antifungal project that I was the lead chemist for was in-licenced by Basilea Pharmaceutica in April 2022. The lead molecule for the antifungal project I designed, synthesized, and scaled up."